Medicines Co buys antibiotic-maker Rempex

Wed Dec 4, 2013 8:57am EST

Dec 4 (Reuters) - Medicines Co on Wednesday said it acquired privately held Rempex Pharmaceuticals Inc, which develops medicines against drug-resistant bacteria, for $140 million and potential future milestone payments of up to $334 million.

Medicines Company said it acquires several anti-infective drugs as part of the deal, including a promising experimental medicine called Carbavance that has completed early-stage trials.

The company said it will continue to develop other experimental drugs from Rempex that also treat gram-negative bacteria in hospital settings.